HOME › Press Releases › Blood Screening Market worth $2.5 Billion by 2019
Blood Screening Market worth $2.5 Billion by 2019
The report “Blood Screening Market by Technology (Nucleic Acid Amplification Test, ELISA, Rapid Test, Chemiluminescence Immunoassay, Next Generation Sequencing, Western Blotting), Product (Instrument, Reagent) & End User (Blood Bank, Hospital) - Forecasts to 2019”, provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the blood screening market along with estimates and forecasts of the revenue and share analysis.
Browse 197 market data tables and 34 figures spread through 230 pages and in-depth TOC on “Blood Screening Market by Technology (Nucleic Acid Amplification Test, ELISA, Rapid Test, Chemiluminescence Immunoassay, Next Generation Sequencing, Western Blotting), Product (Instrument, Reagent) & End User (Blood Bank, Hospital) - Forecasts to 2019"
Early buyers will receive 10% customization on reports.
The global blood screening market is expected to reach $2.5 billion by 2019 from $1.55 billion in 2014, growing at a CAGR of 10.4% from 2014 to 2019.
The report segments the blood screening market on the basis of products and services, technologies, end users, and regions. Among various products, the reagents segment accounted for the largest share of the blood screening market in 2014. This segment is also expected to grow at the highest CAGR during the forecast period owing to the increasing adoption rate of NAT, rising number of blood donations, and growing demand of blood for transfusion.
Based on regions, the global blood screening market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). In 2014, North America accounted for the largest share of the market while Asia witnessed the highest growth rate.
Key players in the blood screening market include Grifols (Spain), Roche Diagnostics (Switzerland), Abbott Laboratories (U.S.), Bio-Rad Laboratories (U.S.), Siemens Healthcare (Germany), bioMérieux (France), Ortho Clinical Diagnostics, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Beckman Coulter (U.S.), Becton Dickinson and Company (U.S.).
MarketsandMarkets is world’s No. 2 firm in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors.
M&M’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers.
We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.
North - Dominion Plaza,
17304 Preston Road,
Suite 800, Dallas, TX 75252